A Phase 2 interventional study of Standard care and Eosinophil-directed care in Asthma Attack and Asthma, sponsored by Changi General Hospital. Completed at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Changi General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.
Among the 25 studies in Asthma with a site in Singapore, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 21st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:
Generate Biomedicines · Sites in Singapore, United States, Brazil and 18 more countries
Ages 12–80
National Healthcare Group Polyclinics · Sites in Singapore
Ages 21–65
Singapore General Hospital · Sites in Singapore
Ages 21–80
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 253 across the 19 interventional studies, 315 across the 6 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 25 have an industry lead sponsor. The 10 most frequent:
Changi General Hospital is the lead sponsor of 101 studies on the registry; 18 are open to participants now.
Changi General Hospital has 2 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Asthma with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Asthma attacks which are moderate-to-severe are typically treated with corticosteroids, but the optimal treatment duration is unknown and treatment responses can be variable. Inadequate treatment may compromise recovery, but increased exposure to corticosteroids is, in turn, associated with drug-related adverse effects.
There is a need for a biomarker to guide duration of corticosteroid treatment in asthma attacks. One such candidate biomarker is the blood eosinophil count, which may predict steroid-responsiveness. We hypothesize that the blood eosinophil count can potentially be used as a biomarker to guide the duration of corticosteroids in moderate-to-severe asthma attacks.
This study will recruit individuals hospitalized for asthma attack. Participants will be randomized to standard care or blood-eosinophil guided systemic corticosteroid therapy. Subjects in the standard arm will receive oral corticosteroids for a total of 5 days. Subjects in the blood-eosinophil guided arm will receive oral corticosteroids for a total of 5 days if admission eosinophil count is ≥ 0.300 x 10\^3/µL, and receive 3 days of oral corticosteroids if the admission blood eosinophil is \< 0.300 x 10\^3/µL. The rate of treatment failure will be compared between these two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Standard care
Other: Eosinophil-directed care
Oral prednisolone for 5 days
Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
Proportion of participants experiencing treatment failure
Defined as death from any cause, or need for invasive/noninvasive mechanical ventilation, or need to restart/extend systemic steroid treatment
Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days
Length of hospital stay (number of days)
Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days
Cumulative steroid dose at index admission (mg prednisolone-equivalent)
Time frame: Through the duration of the index admission for asthma attack, typically 3-5 days
Proportion of participants receiving additional systemic steroid course within 14 days
Time frame: 14 days
Asthma Control Questionnaire-5
Time frame: At baseline, 7, 14, 30 and 90 days
Proportion of participants experiencing all-cause death
Time frame: 30 and 90 days
Proportion of participants who develop pneumonia
Time frame: 30 and 90 days
Proportion of participants who develop venous thromboembolism
Time frame: 30 and 90 days
Proportion of participants who develop sepsis
Time frame: 30 and 90 days
Proportion of participants who develop fractures
Time frame: 30 and 90 days
Proportion of participants who develop upper gastrointestinal bleeds/peptic or gastric ulcers
Time frame: 30 and 90 days
Time to next emergency department visit or admission for asthma
Time frame: 1 year
Plan to share: No
Ran from Jun 2022 to primary completion in May 2024, 23 months.
Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's 23 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2025 → May 2024 and completion Sep 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.